Sanofi SA (NYSE:SNY) – Research analysts at Jefferies Financial Group issued their Q3 2018 earnings per share estimates for Sanofi in a research note issued on Friday, October 12th. Jefferies Financial Group analyst I. Hilliker anticipates that the company will post earnings per share of $0.97 for the quarter. Jefferies Financial Group also issued estimates for Sanofi’s FY2019 earnings at $3.20 EPS, FY2020 earnings at $3.52 EPS, FY2021 earnings at $3.82 EPS and FY2022 earnings at $4.10 EPS.

A number of other brokerages have also recently issued reports on SNY. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “sell” rating in a research note on Tuesday. Guggenheim began coverage on shares of Sanofi in a research note on Monday, October 8th. They issued a “neutral” rating for the company. BNP Paribas raised shares of Sanofi from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 1st. Deutsche Bank reiterated a “buy” rating on shares of Sanofi in a report on Wednesday, August 1st. Finally, Argus upped their price target on shares of Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a report on Friday, August 24th. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $49.00.

Shares of Sanofi stock opened at $44.35 on Monday. Sanofi has a 52-week low of $37.43 and a 52-week high of $50.04. The firm has a market capitalization of $112.04 billion, a PE ratio of 14.09, a price-to-earnings-growth ratio of 2.40 and a beta of 0.82. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85.

Sanofi (NYSE:SNY) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.02. Sanofi had a net margin of 10.29% and a return on equity of 23.77%. The company had revenue of $8.18 billion during the quarter, compared to analysts’ expectations of $8.27 billion. During the same quarter in the prior year, the company earned $1.35 EPS. The firm’s revenue was down 5.6% on a year-over-year basis.

In related news, major shareholder Sanofi sold 104,552 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.00% of the company’s stock.

A number of large investors have recently bought and sold shares of SNY. Fisher Asset Management LLC raised its holdings in Sanofi by 3.6% in the 2nd quarter. Fisher Asset Management LLC now owns 15,622,562 shares of the company’s stock worth $625,059,000 after purchasing an additional 549,110 shares in the last quarter. BlackRock Inc. raised its holdings in Sanofi by 0.7% in the 2nd quarter. BlackRock Inc. now owns 3,328,180 shares of the company’s stock worth $133,161,000 after purchasing an additional 22,425 shares in the last quarter. Brandes Investment Partners LP raised its holdings in Sanofi by 5.0% in the 2nd quarter. Brandes Investment Partners LP now owns 2,851,133 shares of the company’s stock worth $114,074,000 after purchasing an additional 136,316 shares in the last quarter. Northern Trust Corp raised its holdings in Sanofi by 2.3% in the 2nd quarter. Northern Trust Corp now owns 2,209,626 shares of the company’s stock worth $88,407,000 after purchasing an additional 49,233 shares in the last quarter. Finally, Hamlin Capital Management LLC raised its holdings in Sanofi by 16.7% in the 2nd quarter. Hamlin Capital Management LLC now owns 2,066,689 shares of the company’s stock worth $82,688,000 after purchasing an additional 295,930 shares in the last quarter. Institutional investors own 7.54% of the company’s stock.

About Sanofi

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: Dividend

Earnings History and Estimates for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.